|2014||Dual mechanism of interleukin-3 receptor blockade by an anti-cancer antibody.
|Braley, H Hartman, D Parker, MW Hercus, TR Huynh, H Scotney, PD Wilson, NJ Dottore, M Dhagat, U Nash, AD McClure, BJ Kan, WL Owczarek, CM Broughton, SE Barry, EF Busfield, SJ Hardy, MP Lopez, AF|
|2016||Conformational Changes in the GM-CSF Receptor Suggest a Molecular Mechanism for Affinity Conversion and Receptor Signaling
|Broughton, SE Hercus, TR Nero, TL Dottore, M McClure, BJ Dhagat, U Taing, H Gorman, MA King-Scott, J Lopez, AF Parker, MW|
|2016||CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common beta chain of the IL-3, GM-CSF and IL-5 receptors
|Panousis, C Dhagat, U Edwards, KM Rayzman, V Hardy, MP Braley, H Gauvreau, GM Hercus, TR Smith, S Sehmi, R McMillan, L Dottore, M McClure, BJ Fabri, LJ Vairo, G Lopez, AF Parker, MW Nash, AD Wilson, NJ Wilson, MJ Owczarek, CM|
|2018||The mechanism of GM-CSF inhibition by human GM-CSF auto-antibodies suggests novel therapeutic opportunities
|Dhagat, U Hercus, TR Broughton, SE Nero, TL Shing, KSCT Barry, EF Thomson, CA Bryson, S Pai, EF McClure, BJ Schrader, JW Lopez, AF Parker, MW|